

■ **An inactivated H5N1 avian influenza vaccine [Panflu]* has good immunogenicity**, according to preliminary results from a phase I trial. In this double-blind, randomised study, 120 volunteers received either the human-used whole-virus vaccine at four different antigen dosages (n = 96), or placebo. All antigen dosages were associated with an immune response; the 10µg dosage demonstrated the highest immunogenicity, with a seropositive rate of 78.3%. No serious adverse events were reported.

* Sinovac; phase I in China

Sinovac Biotech Ltd. Sinovac Announces Pandemic Influenza Vaccine Phase I Clinical Trial Preliminary Results. Media Release : 19 Jun 2006. Available from: URL: <http://www.sinovac.com> 809064880